<?phpxml version="1.0" encoding="utf-8"?>
<rss version="2.0" 
xmlns:content="http://purl.org/rss/1.0/modules/content/"
xmlns:wfw="http://wellformedweb.org/CommentAPI/"
xmlns:dc="http://purl.org/dc/elements/1.1/"
>
<channel>
<title>World Pharma News .net | Published News</title>
<link>http://www.worldpharmanews.net</link>
<description>Your Source for Social News and Networking</description>
<pubDate>Mon, 30 Aug 2010 21:20:22 EEST</pubDate>
<language>en</language>
<item>
<title><![CDATA[An Increase In Complications Due To Surgical Revision Of Defective Sprint Fidelis Leads - Drug Injury Watch]]></title>
<link>http://www.worldpharmanews.net/Blogs/an-increase-in-complications-due-to-surgical-revision-of-defective-sprint-fidelis-leads-drug-injury-watch/</link>
<comments>http://www.worldpharmanews.net/Blogs/an-increase-in-complications-due-to-surgical-revision-of-defective-sprint-fidelis-leads-drug-injury-watch/</comments>
<pubDate>Mon, 30 Aug 2010 21:20:22 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/Blogs/an-increase-in-complications-due-to-surgical-revision-of-defective-sprint-fidelis-leads-drug-injury-watch/</guid>
<description><![CDATA[Lead Wire Extraction Surgery Might Be More Hazardous Than Once Thought, Including Serious Cardiovascular Injuries And Deaths <br/><br/>9 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Change in environment sparks stem cell cross-over]]></title>
<link>http://www.worldpharmanews.net/Research_Development/change-in-environment-sparks-stem-cell-cross-over/</link>
<comments>http://www.worldpharmanews.net/Research_Development/change-in-environment-sparks-stem-cell-cross-over/</comments>
<pubDate>Sun, 29 Aug 2010 00:19:24 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/Research_Development/change-in-environment-sparks-stem-cell-cross-over/</guid>
<description><![CDATA[EU-funded scientists have discovered that stem cells from one of the immune system's main organs can be reprogrammed to form hair follicle stem cells. The key lies in altering the environment in which the cells are grown. These results demonstrate that it is possible to alter stem cells without genetic manipulation. Details of the study are published in Nature. Ectoderm, endoderm and mesoderm are<br/><br/>7 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Shire Announces European Approval of VPRIV® (velaglucerase alfa)]]></title>
<link>http://www.worldpharmanews.net/Product/shire-announces-european-approval-of-vpriv-velaglucerase-alfa/</link>
<comments>http://www.worldpharmanews.net/Product/shire-announces-european-approval-of-vpriv-velaglucerase-alfa/</comments>
<pubDate>Sun, 29 Aug 2010 00:17:34 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/Product/shire-announces-european-approval-of-vpriv-velaglucerase-alfa/</guid>
<description><![CDATA[Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, announced today that the European Commission has granted marketing authorisation for VPRIV® (velaglucerase alfa), a human cell line derived enzyme replacement therapy (ERT) for the long-term treatment of type 1 Gaucher disease. VPRIV has been authorized as an orphan medicine through the Centralised Procedure, mak<br/><br/>7 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Bristol-Myers Squibb and Pfizer Inc Evaluate Unmet Need in Patients with Atrial Fibrillation]]></title>
<link>http://www.worldpharmanews.net/Product/bristol-myers-squibb-and-pfizer-inc-evaluate-unmet-need-in-patients-with-atrial-fibrillation/</link>
<comments>http://www.worldpharmanews.net/Product/bristol-myers-squibb-and-pfizer-inc-evaluate-unmet-need-in-patients-with-atrial-fibrillation/</comments>
<pubDate>Sun, 29 Aug 2010 00:16:15 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/Product/bristol-myers-squibb-and-pfizer-inc-evaluate-unmet-need-in-patients-with-atrial-fibrillation/</guid>
<description><![CDATA[Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer (NYSE: PFE) report that preliminary results from the Phase 3 AVERROES clinical trial of the investigational drug apixaban compared with acetylsalicylic acid (ASA, or aspirin) in patients with atrial fibrillation expected to be or demonstrated to be unsuitable for warfarin therapy will be presented at the European Society of Cardiology Congress 2<br/><br/>7 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[GSK European Commission amends licence for Cervarix®]]></title>
<link>http://www.worldpharmanews.net/Product/gsk-european-commission-amends-licence-for-cervarix/</link>
<comments>http://www.worldpharmanews.net/Product/gsk-european-commission-amends-licence-for-cervarix/</comments>
<pubDate>Sun, 29 Aug 2010 00:15:12 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/Product/gsk-european-commission-amends-licence-for-cervarix/</guid>
<description><![CDATA[GlaxoSmithKline (GSK) confirmed that the European Commission has granted Marketing Authorisation to amend the licence for its cervical cancer vaccine, Cervarix®. The approval from the European Commission is important as it recognises the extent of cervical cancer protection demonstrated by Cervarix®, which was not highlighted by the previous indication.<br/><br/>7 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Novartis awards 2010 Prizes for Immunology in recognition of outstanding contributions to immunology in medical research]]></title>
<link>http://www.worldpharmanews.net/Corporate/novartis-awards-2010-prizes-for-immunology-in-recognition-of-outstanding-contributions-to-immunology-in-medical-research/</link>
<comments>http://www.worldpharmanews.net/Corporate/novartis-awards-2010-prizes-for-immunology-in-recognition-of-outstanding-contributions-to-immunology-in-medical-research/</comments>
<pubDate>Sun, 29 Aug 2010 00:10:51 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/Corporate/novartis-awards-2010-prizes-for-immunology-in-recognition-of-outstanding-contributions-to-immunology-in-medical-research/</guid>
<description><![CDATA[The Novartis 2010 Immunology Prizes were presented at the 16th International Congress of Immunology in Kobe, Japan. Since 1992, the Novartis Prizes for Immunology have been awarded every third year for outstanding contributions to basic and clinical immunology.<br/><br/>7 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Merck Provides New Funding to Fight HIV/AIDS in Botswana]]></title>
<link>http://www.worldpharmanews.net/Corporate/merck-provides-new-funding-to-fight-hivaids-in-botswana/</link>
<comments>http://www.worldpharmanews.net/Corporate/merck-provides-new-funding-to-fight-hivaids-in-botswana/</comments>
<pubDate>Sun, 29 Aug 2010 00:09:48 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/Corporate/merck-provides-new-funding-to-fight-hivaids-in-botswana/</guid>
<description><![CDATA[Merck announced the Merck Company Foundation and the Bill & Melinda Gates Foundation are committing an additional $60 million to support Botswana's African Comprehensive HIV/AIDS Partnerships (ACHAP). Merck is known as MSD outside the US and Canada.<br/><br/>7 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[World Health Organization Grants Prequalification to Prevenar 13]]></title>
<link>http://www.worldpharmanews.net/Product/world-health-organization-grants-prequalification-to-prevenar-13/</link>
<comments>http://www.worldpharmanews.net/Product/world-health-organization-grants-prequalification-to-prevenar-13/</comments>
<pubDate>Sun, 29 Aug 2010 00:08:36 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/Product/world-health-organization-grants-prequalification-to-prevenar-13/</guid>
<description><![CDATA[The World Health Organization (WHO) has granted prequalification to Prevenar 13 (Pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed])for active immunization of infants and children from 6 weeks through five years of age against invasive disease, pneumonia and otitis media caused by the 13 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F and 23F) contained in t<br/><br/>7 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[GSK commences Phase III clinical trials to develop herpes zoster vaccine for the prevention of shingles]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/gsk-commences-phase-iii-clinical-trials-to-develop-herpes-zoster-vaccine-for-the-prevention-of-shingles/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/gsk-commences-phase-iii-clinical-trials-to-develop-herpes-zoster-vaccine-for-the-prevention-of-shingles/</comments>
<pubDate>Sun, 29 Aug 2010 00:07:28 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/gsk-commences-phase-iii-clinical-trials-to-develop-herpes-zoster-vaccine-for-the-prevention-of-shingles/</guid>
<description><![CDATA[GlaxoSmithKline confirmed that the company has commenced the Phase III clinical trials programme of its candidate herpes zoster vaccine currently being developed for the prevention of shingles. The phase III clinical trials will study more than 30,000 patients globally and will evaluate the efficacy, safety and immunogenicity of the candidate vaccine.<br/><br/>7 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Roche acquires BioImagene, a leading provider of digital pathology laboratory solutions]]></title>
<link>http://www.worldpharmanews.net/Corporate/roche-acquires-bioimagene-a-leading-provider-of-digital-pathology-laboratory-solutions/</link>
<comments>http://www.worldpharmanews.net/Corporate/roche-acquires-bioimagene-a-leading-provider-of-digital-pathology-laboratory-solutions/</comments>
<pubDate>Sun, 29 Aug 2010 00:06:14 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/Corporate/roche-acquires-bioimagene-a-leading-provider-of-digital-pathology-laboratory-solutions/</guid>
<description><![CDATA[Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that it has signed an agreement under which Ventana Medical Systems Inc., a member of the Roche Group, will acquire 100 percent of BioImagene, Inc., a privately held company based in Sunnyvale, California.<br/><br/>7 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Popular Seizure And Bipolar Disorder Medication Lamictal Associated With Aseptic Meningitis In August 2010]]></title>
<link>http://www.worldpharmanews.net/Blogs/popular-seizure-and-bipolar-disorder-medication-lamictal-associated-with-aseptic-meningitis-in-august-2010-1/</link>
<comments>http://www.worldpharmanews.net/Blogs/popular-seizure-and-bipolar-disorder-medication-lamictal-associated-with-aseptic-meningitis-in-august-2010-1/</comments>
<pubDate>Thu, 19 Aug 2010 23:53:40 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/Blogs/popular-seizure-and-bipolar-disorder-medication-lamictal-associated-with-aseptic-meningitis-in-august-2010-1/</guid>
<description><![CDATA[FDA Working With GlaxoSmithKline To Update Label, Or Package Insert, And Patient Medication Guide To Warn About This Side Effect<br/><br/>3 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[What Is New In First Half Of 2010 Concerning Atypical Femur Fractures In Patients Using Bisphosphonates]]></title>
<link>http://www.worldpharmanews.net/Blogs/what-is-new-in-first-half-of-2010-concerning-atypical-femur-fractures-in-patients-using-bisphosphonates-1/</link>
<comments>http://www.worldpharmanews.net/Blogs/what-is-new-in-first-half-of-2010-concerning-atypical-femur-fractures-in-patients-using-bisphosphonates-1/</comments>
<pubDate>Wed, 30 Jun 2010 22:14:35 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/Blogs/what-is-new-in-first-half-of-2010-concerning-atypical-femur-fractures-in-patients-using-bisphosphonates-1/</guid>
<description><![CDATA[Fosamax, Boniva, And Other Drugs In This Class Are Under Scrutiny Due To This Emerging Drug Safety Issue (Posted by Tom Lamb at DrugInjuryWatch.com)<br/><br/>17 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[June 2010: FDA Launches Its Postmarketing Drug Safety Evaluations Web Site  - Drug Injury Watch]]></title>
<link>http://www.worldpharmanews.net/Blogs/june-2010-fda-launches-its-postmarketing-drug-safety-evaluations-web-site-drug-injury-watch/</link>
<comments>http://www.worldpharmanews.net/Blogs/june-2010-fda-launches-its-postmarketing-drug-safety-evaluations-web-site-drug-injury-watch/</comments>
<pubDate>Thu, 17 Jun 2010 23:52:14 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/Blogs/june-2010-fda-launches-its-postmarketing-drug-safety-evaluations-web-site-drug-injury-watch/</guid>
<description><![CDATA[New FDA Site Will Include A Summary Analysis Of Recently Reported Adverse Events And Related Medical Articles (Posted by Tom Lamb at DrugInjuryWatch.com)<br/><br/>13 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Blood Pressure Medication Benicar (Olmesartan) Might Be Unsafe For Some Patients - Drug Injury Watch]]></title>
<link>http://www.worldpharmanews.net/Blogs/blood-pressure-medication-benicar-olmesartan-might-be-unsafe-for-some-patients-drug-injury-watch/</link>
<comments>http://www.worldpharmanews.net/Blogs/blood-pressure-medication-benicar-olmesartan-might-be-unsafe-for-some-patients-drug-injury-watch/</comments>
<pubDate>Sat, 12 Jun 2010 00:23:42 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/Blogs/blood-pressure-medication-benicar-olmesartan-might-be-unsafe-for-some-patients-drug-injury-watch/</guid>
<description><![CDATA[Two Clinical Studies Find Patients With Type 2 Diabetes Taking Benicar Had Higher Rate Of Death From A Cardiovascular Cause<br/><br/>14 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[June 2010 Update On Several Possible Zocor (Simivastatin) Side Effects - Drug Injury Watch]]></title>
<link>http://www.worldpharmanews.net/Blogs/june-2010-update-on-several-possible-zocor-simivastatin-side-effects-drug-injury-watch/</link>
<comments>http://www.worldpharmanews.net/Blogs/june-2010-update-on-several-possible-zocor-simivastatin-side-effects-drug-injury-watch/</comments>
<pubDate>Tue, 08 Jun 2010 00:28:40 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/Blogs/june-2010-update-on-several-possible-zocor-simivastatin-side-effects-drug-injury-watch/</guid>
<description><![CDATA[From Myopathy And Rhabdomyolysis To Tendon Ruptures And Interstitial Lung Disease <br/><br/>14 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Serevent, Advair, and Foradil: Despite The Increased Risk of Severe Asthma Episodes and Death, Monotherapy Use Continues]]></title>
<link>http://www.worldpharmanews.net/Blogs/serevent-advair-and-foradil-despite-the-increased-risk-of-severe-asthma-episodes-and-death-monotherapy-use-continues-1/</link>
<comments>http://www.worldpharmanews.net/Blogs/serevent-advair-and-foradil-despite-the-increased-risk-of-severe-asthma-episodes-and-death-monotherapy-use-continues-1/</comments>
<pubDate>Wed, 12 May 2010 23:48:20 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/Blogs/serevent-advair-and-foradil-despite-the-increased-risk-of-severe-asthma-episodes-and-death-monotherapy-use-continues-1/</guid>
<description><![CDATA[Numerous Safety Warnings From FDA About These LABA Asthma Drugs Have Seemingly Been Ignored By Patients, According To New Medco Study<br/><br/>17 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Study Gives Better Understanding Of How Reoviruses And Chemo Work Together | The Investor Relations Group]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/study-gives-better-understanding-of-how-reoviruses-and-chemo-work-together-%7C-the-investor-relations-group/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/study-gives-better-understanding-of-how-reoviruses-and-chemo-work-together-%7C-the-investor-relations-group/</comments>
<pubDate>Wed, 12 May 2010 21:53:52 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/study-gives-better-understanding-of-how-reoviruses-and-chemo-work-together-%7C-the-investor-relations-group/</guid>
<description><![CDATA[As effective as Gemcitabine is against some cancers, it has not been proven effective as a standalone treatment for eradicating certain other forms such as colon cancer. However, researchers at Weill Cornell Medical Center in New York have demonstrated that a reovirus therapy called REOLYSIN works synergistically with gemcitabine and may be worth further investigation. <br/><br/>16 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Vaccines For HIV And AIDS On The Horizon | The Investor Relations Group]]></title>
<link>http://www.worldpharmanews.net/ClinicalTrials/vaccines-for-hiv-and-aids-on-the-horizon-%7C-the-investor-relations-group/</link>
<comments>http://www.worldpharmanews.net/ClinicalTrials/vaccines-for-hiv-and-aids-on-the-horizon-%7C-the-investor-relations-group/</comments>
<pubDate>Wed, 12 May 2010 18:36:37 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/ClinicalTrials/vaccines-for-hiv-and-aids-on-the-horizon-%7C-the-investor-relations-group/</guid>
<description><![CDATA[A company named GeoVax Labs, Inc. may be the first to put vaccines on the market that can help alleviate the suffering that results when HIV progresses to AIDS. Based in Smyrna, GA., the company is at work on both preventative and therapeutic vaccines.<br/><br/>18 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Chembio to Sponsor AIDS Walk New York 2010 | The Investor Relations Group]]></title>
<link>http://www.worldpharmanews.net/Corporate/chembio-to-sponsor-aids-walk-new-york-2010-%7C-the-investor-relations-group-1/</link>
<comments>http://www.worldpharmanews.net/Corporate/chembio-to-sponsor-aids-walk-new-york-2010-%7C-the-investor-relations-group-1/</comments>
<pubDate>Wed, 12 May 2010 18:34:23 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/Corporate/chembio-to-sponsor-aids-walk-new-york-2010-%7C-the-investor-relations-group-1/</guid>
<description><![CDATA[Not only is Chembio among the walk's sponsors; company employees will also be participating in this historic walk to raise funds for AIDS research.<br/><br/>21 Vote(s) ]]></description>
</item>

<item>
<title><![CDATA[Derma Sciences Opens First International Office in London | The Investor Relations Group]]></title>
<link>http://www.worldpharmanews.net/Corporate/derma-sciences-opens-first-international-office-in-london-%7C-the-investor-relations-group/</link>
<comments>http://www.worldpharmanews.net/Corporate/derma-sciences-opens-first-international-office-in-london-%7C-the-investor-relations-group/</comments>
<pubDate>Wed, 12 May 2010 18:30:08 EEST</pubDate>
<dc:creator></dc:creator>
<category></category>
<guid>http://www.worldpharmanews.net/Corporate/derma-sciences-opens-first-international-office-in-london-%7C-the-investor-relations-group/</guid>
<description><![CDATA[Derma Sciences also announced that it has hired Maeve Kelly as Managing Director, EMEA (Europe, Middle East, Africa regions).  Ms. Kelly will report directly to Barry J. Wolfenson, Executive Vice President of Global Marketing and Business Development.<br/><br/>13 Vote(s) ]]></description>
</item>

</channel>
</rss>
